Bristol-Myers Squibb Company (BMY)
| Market Cap | 115.69B |
| Revenue (ttm) | 47.44B |
| Net Income (ttm) | -7.26B |
| Shares Out | 2.03B |
| EPS (ttm) | -3.58 |
| PE Ratio | n/a |
| Forward PE | 8.31 |
| Dividend | $2.48 (4.35%) |
| Ex-Dividend Date | Jan 3, 2025 |
| Volume | 7,007,843 |
| Open | 56.63 |
| Previous Close | 56.29 |
| Day's Range | 56.57 - 57.68 |
| 52-Week Range | 39.35 - 61.08 |
| Beta | 0.45 |
| Analysts | Hold |
| Price Target | 56.29 (-1.31%) |
| Earnings Date | Feb 6, 2025 |
About BMY
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esop... [Read more]
Financial Performance
In 2023, BMY's revenue was $45.01 billion, a decrease of -2.50% compared to the previous year's $46.16 billion. Earnings were $8.03 billion, an increase of 26.84%.
Financial StatementsAnalyst Forecast
According to 15 analysts, the average rating for BMY stock is "Hold." The 12-month stock price forecast is $56.29, which is a decrease of -1.31% from the latest price.
News
Top 4 Immunology Stocks Poised For Growth In 2025
This article will reveal an in-depth analysis of drugs being developed to combat immunological disorders. Big Pharma is keenly interested in the global immunology drugs market, which is anticipated to...
Bristol Myers Squibb says Alzheimer's is the biggest market for new schizophrenia drug
Bristol Myers Squibb believes Alzheimer's treatment is the largest potential market for its newly approved schizophrenia drug, Cobenfy, which it expects to eventually generate billions of dollars in s...
Feedback on schizophrenia treatment has been great, says Bristol Myers Squibb CEO
Bristol Myers Squibb CEO Christopher Boerner joins 'Mad Money' host Jim Cramer to talk its new schizophrenia treatment Cobenfy, its oncology business, and more.
Bristol-Myers Squibb Company (BMY) 43rd Annual J.P. Morgan Healthcare Conference (Transcript)
Bristol-Myers Squibb Company (NYSE:BMY) 43rd Annual J.P. Morgan Healthcare Conference January 13, 2024 10:30 AM ET Company Participants Chris Boerner - Chairman and Chief Executive Officer Conference...
ArsenalBio and Bristol Myers Squibb Achieve Milestone for AB-4000 Series as Part of Ongoing Multi-Program Collaboration to Advance Next-Generation T Cell Therapies for Solid Tumors
ArsenalBio and Bristol Myers Squibb achieve milestone for AB-4000 series as part of a multi-program collaboration to advance next-gen T cell therapies.
Buy 6 'Safer' Dividend Dogs Of 23 January Barron's Better Bets Than T-Bills
Seven of the ten lowest-priced BBB Dogs, including Altria, Pfizer, and Verizon, are ready to buy, with dividends from $1K invested exceeding single share prices. Analysts project 16.27% to 32.98% net ...
Healthcare has 'been so bad, maybe it's gonna be good' in 2025, says Mizuho's Jared Holz
Jared Holz, Mizuho Securities America healthcare sector strategist, joins CNBC's 'Squawk on the Street' to discuss outlooks on the healthcare sector in the new year
Bristol Myers Squibb to Present at J.P. Morgan's 43rd Annual Healthcare Conference
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Present at J.P. Morgan's 43rd Annual Healthcare Conference.
Final Trade: XLE, PANW, XHB, BMY
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Drugmakers to raise US prices on over 250 medicines starting Jan. 1
Drugmakers plan to raise U.S. prices on at least 250 branded medications including Pfizer COVID-19 treatment Paxlovid, Bristol Myers Squibb's cancer cell therapies and vaccines from France's Sanofi at...
Bristol-Myers Squibb Stock: Clearly Undervalued, Excellent 2H24 Culminates In Opdivo 'Subcu' Approval
Bristol-Myers Squibb Stock: Clearly Undervalued, Excellent 2H24 Culminates In Opdivo 'Subcu' Approval
U.S. Food and Drug Administration Approves Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy) Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo® (nivolumab) Indications1,2
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CheckMate--US FDA Approves Opdivo Qvantig Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo Indications.
US FDA approves injectable form of Bristol Myers' Opdivo
The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb's blockbuster cancer drug, Opdivo.
Bristol Myers Squibb Announces Positive Topline Results from Two Pivotal Phase 3 Trials Evaluating Sotyktu (deucravacitinib) in Adults with Psoriatic Arthritis
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #POETYK--BMS Announces Positive Topline Results from Two Pivotal Phase 3 Trials Evaluating Sotyktu (deucravacitinib) in Adults with Psoriatic Arthritis.
Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult.
Bristol-Myers Squibb: Rich Dividends & Double-Digits Upside Potential - Bright 2026 Prospects
BMY has had a robust H1'24 stock price performance, aided by the July/ August 2024 market rotation and the US FDA timely approval of its acquired schizophrenia therapy. These build upon the 8 new onco...
Bristol-Myers Squibb Will Handle The Patent Cliff And Is Still Undervalued
Bristol-Myers Squibb remains a "Buy" despite recent price increases, with intrinsic value calculations showing the stock is still undervalued. The company faces risks from patent expirations but has p...
Imbed Biosciences Appoints Bristol Myers Squibb Veteran Terry Bromley as Chief Executive Officer
MIDDLETON, Wis.--(BUSINESS WIRE)-- #HealthtechInnovation--Imbed Biosciences today announced that Terry Bromley has joined as Chief Executive Officer. With over 30 years of experience in the medical de...
Bristol Myers Squibb to Report Results for Fourth Quarter 2024 on February 6, 2025
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Report Results for Fourth Quarter 2024 on February 6, 2025.
BioArctic announces global license agreement with Bristol Myers Squibb for BioArctic's PyroGlutamate-amyloid-beta antibody program
STOCKHOLM , Dec. 19, 2024 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that it has entered into a global exclusive license agreement with Bristol Myers Squibb (NYSE: ...
Fangzhou Inc. and Bristol Myers Squibb China Join Forces on a Strategic Alliance to Advance Internet Healthcare
SHANGHAI , Dec. 18, 2024 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a pioneer in Internet healthcare solutions, announced a strategic alliance with Bristol Myers Squibb ("...
Bristol-Myers: Still An Opportunity Yielding Over 4%
Bristol-Myers Squibb has rallied over 35% in the past 6 months, with shares approaching $60 and a price target of $70. BMY's strong dividend yield exceeds 4%, and strategic acquisitions are expected t...
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Bristol Myers Squibb Announces Dividend Increase
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Announces Dividend Increase.